The sine qua non of discovering novel biomarkers for early detection of ovarian cancer: carefully selected preclinical samples
- PMID: 21372028
- DOI: 10.1158/1940-6207.CAPR-11-0048
The sine qua non of discovering novel biomarkers for early detection of ovarian cancer: carefully selected preclinical samples
Abstract
This perspective discusses reports by Cramer and colleagues (beginning on page 365 in this issue of the journal) and Zhu and colleagues (beginning on page 375), which provide the first systematic and reliable comparison of a large number of candidate biomarkers for the early detection of ovarian cancer in a sample set well-suited for this purpose. This research has important implications for the future design of cancer biomarker studies.
Comment on
-
Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens.Cancer Prev Res (Phila). 2011 Mar;4(3):365-74. doi: 10.1158/1940-6207.CAPR-10-0195. Cancer Prev Res (Phila). 2011. PMID: 21372036 Free PMC article.
-
A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer.Cancer Prev Res (Phila). 2011 Mar;4(3):375-83. doi: 10.1158/1940-6207.CAPR-10-0193. Cancer Prev Res (Phila). 2011. PMID: 21372037 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical